Literature DB >> 26942162

Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy.

Hee Jung Yi1, Kyung Sook Hong1, Nara Moon1, Soon Sup Chung1, Ryung-Ah Lee1, Kwang Ho Kim1.   

Abstract

5-Fluorouracil (5-FU) based chemotherapy has been commonly used to treat metastatic or advanced colon cancer as an adjuvant chemotherapy. Although the side effects of 5-FU such as gastrointestinal problems and neutropenia and thrombocytopenia are common, not many cases of 5-FU related encephalopathy are reported. Hyperammonemic encephalopathy is a rare central nervous system toxicity following 5-FU chemotherapy manifesting as altered mental status with elevated ammonia levels with no radiologic abnormality. We report one case of 5-FU induced hyperammonemic encephalopathy occurring after Folfox4 (oxaliplatin, folinic acid and 5-fluorouracil) chemotherapy in a colon cancer patient who presented with confused mental status soon after the chemotherapy and review the 5-FU related encephalopathy.

Entities:  

Keywords:  5-Fluorouracil; Colorectal neoplasma; Hyperammonemia; Metabolic brain diseases

Year:  2016        PMID： 26942162      PMCID： PMC4773463          DOI： 10.4174/astr.2016.90.3.179

Source DB:  PubMed          Journal:  Ann Surg Treat Res        ISSN： 2288-6575            Impact factor:   1.859


  10 in total

1.  Moving beyond fluorouracil for colorectal cancer.

Authors:  R J Mayer
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

2.  5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.

Authors:  Pooja P Advani; Marwan G Fakih
Journal:  Anticancer Res       Date:  2011-01       Impact factor: 2.480

3.  Posterior reversible encephalopathy syndrome (PRES) after treatment with oxaliplatin and 5-fluorouracil.

Authors:  Nicholas Truman; Daniel Nethercott
Journal:  Clin Colorectal Cancer       Date:  2012-08-21       Impact factor: 4.481

4.  Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.

Authors:  Yu-Y Chang; J-K Lin; J-K Jiang
Journal:  Colorectal Dis       Date:  2012-12       Impact factor: 3.788

5.  Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate.

Authors:  H Koenig; A Patel
Journal:  Arch Neurol       Date:  1970-08

6.  Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.

Authors:  J Volk; F Reinke; A B van Kuilenburg; A H van Gennip; C Schlichting; A Ganser; P Schöffski
Journal:  Ann Oncol       Date:  2001-04       Impact factor: 32.976

7.  The aggravating factors of hyperammonemia related to 5-fluorouracil infusion--a report of two cases.

Authors:  Shu Kikuta; Takahiro Asakage; Kazunari Nakao; Masashi Sugasawa; Akatsuki Kubota
Journal:  Auris Nasus Larynx       Date:  2007-09-10       Impact factor: 1.863

Review 8.  Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.

Authors:  M Malet-Martino; R Martino
Journal:  Oncologist       Date:  2002

9.  [A case of hyperammonemic encephalopathy in a patient with recurrent colon cancer treated with modified FOLFOX6].

Authors:  Fuminori Teraishi; Takeo Suzuki; Masako Nakamoto; Akira Chikuba; Masashi Nezu; Hiroshi Shimamura; Takamasa Watanabe; Tadakazu Matsuda; Takao Takiue; Hiroshi Chikuba
Journal:  Gan To Kagaku Ryoho       Date:  2009-05

10.  Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy.

Authors:  Luiz Carlos Porcello Marrone; Bianca Fontana Marrone; Tharick Ali Pascoal; Lucas Porcello Schilling; Ricardo Bernardi Soder; Sheila Schuch Ferreira; Giovani Gadonski; Jaderson Costa da Costa
Journal:  Case Rep Oncol Med       Date:  2013-02-27
  10 in total
  6 in total

1.  5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer.

Authors:  Gyanendra Acharya; Maria T Cruz Carreras; Terry Wynne Rice
Journal:  BMJ Case Rep       Date:  2017-11-21

2.  Hyperammonemic encephalopathy associated with 5-fluorouracil in a patient with previous orthotopic liver transplantation.

Authors:  Hemnishil K Marella; Rahul Peravali; Amit L Jain; Satheesh Nair; Benedict Maliakkal; Uchenna Agbim; Rajanshu Verma
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-01-09

3.  Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database.

Authors:  Alexander Balcerac; Kevin Bihan; Bénédicte Lebrun-Vignes; Dominique Thabut; Joe-Elie Salem; Nicolas Weiss
Journal:  Ann Intensive Care       Date:  2022-06-18       Impact factor: 10.318

4.  The Acute Effects of 5 Fluorouracil on Skeletal Muscle Resident and Infiltrating Immune Cells in Mice.

Authors:  Brandon N VanderVeen; Alexander T Sougiannis; Kandy T Velazquez; James A Carson; Daping Fan; E Angela Murphy
Journal:  Front Physiol       Date:  2020-12-07       Impact factor: 4.566

5.  Oxaliplatin-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Pancreatic Cancer: A Case Report.

Authors:  Takatsugu Ogata; Hironaga Satake; Misato Ogata; Yukimasa Hatachi; Hisateru Yasui
Journal:  Case Rep Oncol       Date:  2017-10-10

Review 6.  Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.

Authors:  Seiichiro Mitani; Shigenori Kadowaki; Azusa Komori; Keiji Sugiyama; Yukiya Narita; Hiroya Taniguchi; Takashi Ura; Masashi Ando; Yozo Sato; Hidekazu Yamaura; Yoshitaka Inaba; Makoto Ishihara; Tsutomu Tanaka; Masahiro Tajika; Kei Muro
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.